Buchumschlag

Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis

Purpose: We aimed to identify subsets of patients who benefit from emergency LA and to establish a therapeutic algorithm for AML patients with hyperleukocytosis. Methods: In this single-center retrospective cohort study, a total of 20 consecutive patients underwent LA because of their clinical sympt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Farid, Kiavasch (VerfasserIn) , Sauer, Tim (VerfasserIn) , Schmitt, Michael (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Schmitt, Anita (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2024
In: Cancers
Year: 2024, Jahrgang: 16, Heft: 1, Pages: 1-17
ISSN:2072-6694
DOI:10.3390/cancers16010058
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers16010058
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/16/1/58
Volltext
Verfasserangaben:Kiavasch Mohammad Nejad Farid, Tim Sauer, Michael Schmitt, Carsten Müller-Tidow and Anita Schmitt
Beschreibung
Zusammenfassung:Purpose: We aimed to identify subsets of patients who benefit from emergency LA and to establish a therapeutic algorithm for AML patients with hyperleukocytosis. Methods: In this single-center retrospective cohort study, a total of 20 consecutive patients underwent LA because of their clinical symptoms. Overall survival (OS) analysis was conducted using the Kaplan-Meier plot method. Univariate and multivariate analyses (using multiple logistic regression) were performed. At the time of diagnosis, all patients received a standard diagnostic workup for AML including FLT3-ITD mutational analysis. Results: FLT3-ITD mut AML patients receiving LA had a median OS of 437 days (range 5-2379 days) with a corresponding 14-day survival of 92.3%, while FLT3 wt AML patients displayed a significantly lower median OS of only 5 days (range 1-203 days) with a corresponding 14-day survival of 14.3% (p = 0.0001). Conclusions: Among patients with clinical symptoms of leukostasis, the subset of FLT3-ITD mut AML patients showed a better outcome with lower early mortality after emergency LA. Based on these observations, we established a therapeutic algorithm for AML patients with hyperleukocytosis.
Beschreibung:Gesehen am 08.05.2024
Beschreibung:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers16010058

Ähnliche Einträge